BLENREP MoA
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
For Great Britain (GB) healthcare professionals only - BLENREP is not available in Northern Ireland (NI).
BLENREP has a conditional marketing authorisation.
BLENREP is the first and only licensed B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for triple-class refractory 5th line plus multiple myeloma1
BLENREP is only available via the private market.
What is BCMA?
BCMA is an ideal target in multiple myeloma. BCMA is:2
What is BLENREP?
Prescribing information can be found at the top of this webpage, or here.
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1
ADCC, antibody-dependent cellular cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; BCMA, B-cell maturation antigen; DREAMM-2, DRiving Excellence in Approaches to Multiple Myeloma 2; ECP, eye care professional; ESMO, European Society for Medical Oncology; FAQ, frequently asked questions; ISS, international staging system; MoA, mechanism of action;
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or email us on UKSafety@gsk.com.
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
February 2024 | PM-GB-BLM-WCNT-220005 (V6.0)